Literature DB >> 21154739

Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract.

Mashaal Dhir1, Shinichi Yachida, Leander Van Neste, Sabine C Glöckner, Jana Jeschke, Emmanouil P Pappou, Elizabeth A Montgomery, James G Herman, Stephen B Baylin, Christine Iacobuzio-Donahue, Nita Ahuja.   

Abstract

The diagnosis of sessile serrated adenomas (SSAs) is challenging, and there is a great deal of interobserver variability amongst pathologists in differentiating SSAs from hyperplastic polyps (HPPs). The aim of this study was (i) to assess the utility of epigenetic changes such as DNA methylation in differentiating SSAs from HPPs and (ii) to identify common methylation based molecular markers potentially useful for early detection of premalignant neoplastic lesions of gastrointestinal tract. A total of 97 primary patient adenoma samples were obtained from The Johns Hopkins Hospital pathology archive with IRB approval and HIPAA compliance. We analyzed the promoter associated CpG island methylation status of 17 genes using nested multiplex methylation specific PCR (MSP). Methylation of CDX2, hMLH1 and TLR2 was detected in SSAs and SSAs with dysplasia but not in HPPs. A subset of genes including EVL, GATAs (4 and 5), HIN-1, SFRPs (1, 2, 4 and 5), SOX17 and SYNE1 were methylated frequently in all premalignant gastrointestinal adenomas including tubular adenomas, villous adenomas, SSAs and SSAs with dysplasia but infrequently in non-premalignant polyps such as HPPs. Methylation of CDX2, hMLH1 and TLR2 may be of diagnostic utility in differentiating, histologically challenging cases of SSAs from HPPs. Genes such as EVL, GATAs, HIN-1, SFRPs, SOX17 and SYNE1, which are frequently methylated in all types of tested premalignant adenomas, may be useful as biomarkers in stool-based strategies for early detection of these adenomas and CRCs in future.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21154739      PMCID: PMC3206997          DOI: 10.1002/ijc.25847

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

Review 1.  Colorectal serrated adenocarcinoma.

Authors:  M J Mäkinen
Journal:  Histopathology       Date:  2007-01       Impact factor: 5.087

2.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Authors:  Daniel J Weisenberger; Kimberly D Siegmund; Mihaela Campan; Joanne Young; Tiffany I Long; Mark A Faasse; Gyeong Hoon Kang; Martin Widschwendter; Deborah Weener; Daniel Buchanan; Hoey Koh; Lisa Simms; Melissa Barker; Barbara Leggett; Joan Levine; Myungjin Kim; Amy J French; Stephen N Thibodeau; Jeremy Jass; Robert Haile; Peter W Laird
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

Review 3.  Serrated adenoma of the colorectum and the DNA-methylator phenotype.

Authors:  Jeremy R Jass
Journal:  Nat Clin Pract Oncol       Date:  2005-08

Review 4.  Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept.

Authors:  Dale C Snover; Jeremy R Jass; Cecilia Fenoglio-Preiser; Kenneth P Batts
Journal:  Am J Clin Pathol       Date:  2005-09       Impact factor: 2.493

5.  Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter.

Authors:  J C Brandes; H Carraway; J G Herman
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

6.  Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.

Authors:  Zsolt Petko; Mahan Ghiassi; Anthony Shuber; Janice Gorham; Walter Smalley; M Kay Washington; Stephen Schultenover; Shiva Gautam; Sanford D Markowitz; William M Grady
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

7.  DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene.

Authors:  Wei Zhang; Michael Bauer; Roland S Croner; Jörg O W Pelz; Dimitri Lodygin; Heiko Hermeking; Michael Stürzl; Werner Hohenberger; Klaus E Matzel
Journal:  Dis Colon Rectum       Date:  2007-10       Impact factor: 4.585

8.  Progressive methylation during the serrated neoplasia pathway of the colorectum.

Authors:  Seung M Dong; Eui J Lee; Eun S Jeon; Cheol K Park; Kyoung-Mee Kim
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

9.  Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases.

Authors:  Neal S Goldstein
Journal:  Am J Clin Pathol       Date:  2006-01       Impact factor: 2.493

10.  Hyperplastic polyps and sessile serrated 'adenomas' of the colon and rectum display gastric pyloric differentiation.

Authors:  Akiyoshi Mochizuka; Takeshi Uehara; Takamichi Nakamura; Yukihiro Kobayashi; Hiroyoshi Ota
Journal:  Histochem Cell Biol       Date:  2007-09-12       Impact factor: 4.304

View more
  26 in total

1.  Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia.

Authors:  Xinwei Hua; Polly A Newcomb; Jessica Chubak; Rachel C Malen; Rebecca Ziebell; Aruna Kamineni; Lee-Ching Zhu; Melissa P Upton; Michelle A Wurscher; Sushma S Thomas; Hana Newman; Sheetal Hardikar; Andrea N Burnett-Hartman
Journal:  Cancer Causes Control       Date:  2020-05-01       Impact factor: 2.506

Review 2.  Epigenetics and colorectal cancer.

Authors:  Victoria Valinluck Lao; William M Grady
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-18       Impact factor: 46.802

3.  The role of APC in WNT pathway activation in serrated neoplasia.

Authors:  Jennifer Borowsky; Troy Dumenil; Mark Bettington; Sally-Ann Pearson; Catherine Bond; Lochlan Fennell; Cheng Liu; Diane McKeone; Christophe Rosty; Ian Brown; Neal Walker; Barbara Leggett; Vicki Whitehall
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

4.  Comprehensive DNA Methylation and Mutation Analyses Reveal a Methylation Signature in Colorectal Sessile Serrated Adenomas.

Authors:  Árpád V Patai; Barbara Kinga Barták; Bálint Péterfia; Tamás Micsik; Réka Horváth; Csaba Sumánszki; Zoltán Péter; Árpád Patai; Gábor Valcz; Alexandra Kalmár; Kinga Tóth; Tibor Krenács; Zsolt Tulassay; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2016-11-29       Impact factor: 3.201

Review 5.  [Serrated precursor lesions].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

6.  Distinct WNT/β-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum.

Authors:  Takashi Murakami; Hiroyuki Mitomi; Tsuyoshi Saito; Michiko Takahashi; Naoto Sakamoto; Naoshi Fukui; Takashi Yao; Sumio Watanabe
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

7.  Usefulness of the Japan narrow-band imaging expert team classification system for the diagnosis of sessile serrated lesion with dysplasia/carcinoma.

Authors:  Takashi Murakami; Naoto Sakamoto; Hirofumi Fukushima; Tomoyoshi Shibuya; Takashi Yao; Akihito Nagahara
Journal:  Surg Endosc       Date:  2020-09-09       Impact factor: 4.584

Review 8.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

Review 9.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 10.  Pathological features of the sessile serrated adenoma/polyp with special references of its carcinogenesis.

Authors:  Ryo Wada; Toshio Morimoto; Tatsuya Inayoshi
Journal:  Med Mol Morphol       Date:  2014-04-20       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.